150
Participants
Start Date
January 17, 2025
Primary Completion Date
December 31, 2027
Study Completion Date
December 31, 2027
RBS2418
RBS2418 is a specific immune modulator that works through the inhibition of ectonucleotide pyrophosphatase/phosphodiesterase 1 (ENPP1) and is designed to lead to anti-tumor immunity by protecting endogenous 2'-3'-cyclic guanosine monophosphate-adenosine monophosphate (cGAMP) from hydrolysis and leading to the activation of antigen-presenting cells followed by T cell activation.
Placebo
Placebo to Match RBS2418
RECRUITING
Tam Anh, Ha Noi General Hospital, Hanoi
RECRUITING
Tam Anh TP. Ho Chi Minh General Hospital, Ho Chi Minh City
NOT_YET_RECRUITING
University of California, Los Angeles, Los Angeles
Tam Anh Research Institute
OTHER
Riboscience, LLC.
INDUSTRY